electroCore, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28531P2020
USD
4.95
0.2 (4.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About electroCore, Inc. stock-summary
stock-summary
electroCore, Inc.
Pharmaceuticals & Biotechnology
ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.
Company Coordinates stock-summary
Company Details
150 Allen Rd Ste 201 , Basking Ridge NJ : 07920-2977
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (4.7%)

Foreign Institutions

Held by 9 Foreign Institutions (1.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Atieh
Independent Chairman of the Board
Mr. Daniel Goldberger
Chief Executive Officer, Director
Mr. Joseph Errico
Director
Mr. Peter Cuneo
Independent Director
Dr. Thomas Errico
Independent Director
Mr. John Gandolfo
Independent Director
Mr. Trevor Moody
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 37 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-6.28

stock-summary
Return on Equity

-1,190.57%

stock-summary
Price to Book

33.52